Posts tagged business development
Ladenburg ups Novavax PT to $3.50 from $2.50

Ladenburg Thalmann raised its price target for Novavax (NASDAQ:NVAX) to $3.50 from $2.50 after the company presented Phase 1/2 data suggesting its NanoFlu vaccine has the potential to be the most potent product for preventing flu, including the Singapore A strain that is expected to be a dominant strain for the 2019-2020 flu season.

Read More
HCW downgrades Proteon to neutral

H.C. Wainwright downgraded Proteon Therapeutics (NASDAQ:PRTO) to “neutral” from “buy” and slashed its price target to $3 from $18, citing a lack of major catalysts that will likely render the shares range-bound. The stock closed at $1.75 on March 16.

Read More
HCW starts Bellerophon Therapeutics at buy

H.C. Wainwright initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and price target of $5. The stock closed at 67 cents on Jan. 20.

Read More
Jason Flowerday named CEO of 3D Signatures

3D Signatures (TSX-V:DXD) has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the board.

"Mr. Flowerday is a highly respected biotech entrepreneur with more than 20 years of executive life sciences management and startup experience. He has the entrepreneurial and management skills we need to drive us to commercialization," John Swift, chairman, said in a statement.

Read More
Merus Labs appoints two senior executives

Merus Labs International (NASDAQ:MSLI; TSX:MSL) has appointed two key additions to its executive leadership team, effective July 1.

Dr. Michael Bumby was named CFO, succeeding Andrew Patient, who has decided to leave the company to pursue other opportunities. Mr. Patient will remain with Merus Labs for a period of time to ensure a smooth transition.

Read More
Soricimed names Cory VP of BD, Reeves chairman

Closely-held Soricimed Biopharma has named Bob Cory as VP of business development and appointed Tom Reeves, a director, as chairman.

Dr. Cory has over 20 years of business and corporate development leadership experience in the biopharmaceutical industry. Most recently, he was VP of business development with Qu Biologics. Mr. Reeves currently is president and CEO of closely-held Interface Biologics.

Read More